NASDAQ$ROIV
Roivant Sciences Ltd · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
Reported Q1 FY2026 with $2.17M in revenue, a GAAP net loss of $223.4M (EPS -$0.33), and continued investment in R&D and G&A while maintaining a strong liquidity position.
Roivant posted modest revenue alongside a larger operating loss as it advanced multiple late-stage programs. GAAP EPS was -$0.33 and non-GAAP adjusted EPS was approximately -$0.25 based on adjusted net loss and shares outstanding. The company ended the quarter with a robust cash and investments balance and continued share repurchases.
- Revenue was $2.17M; cost of revenue $0.15M.
- GAAP net loss attributable to Roivant was $223.4M; EPS -$0.33.
- Non-GAAP adjusted loss from continuing operations implied adjusted EPS of about -$0.25.
- Consolidated cash, cash equivalents and restricted cash totaled ~$1.25B; marketable securities ~$3.26B.
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$2.17M
Forward guidance
The company did not provide quantitative financial guidance; updates focused on clinical milestones, litigation timelines, and capital allocation.
Tailwinds
- Phase 3 VALOR DM topline data expected in 2H 2025.
- Active enrollment across multiple IMVT-1402 registrational programs.
- Strong liquidity with ~$4.5B in cash and marketable securities.
- Completion of $1.5B buyback and authorization of additional $500M.
- Multiple additional program readouts planned through 2026–2027.
Headwinds
- Operating loss widened with higher R&D and G&A expenses.
- Limited current-period revenue contribution.
- No specific near-term financial guidance provided.
- Ongoing legal proceedings (LNP litigation) create uncertainty.
- Execution risk around numerous late-stage clinical milestones.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro